Bind, Macrophage to Develop Accurin Nanoparticles

Bind Therapeutics has entered into a research collaboration with Macrophage Therapeutics to create Accurins, Bind’s programmable nanoparticle therapeutics, engineered using Macrophage’s Manocept targeting platform.

Accurins provide selective targeting of cancerous tissue while avoiding harming white blood cells. The particles can potentially be designed to fight inflammatory, vascular and infectious disease.

Cambridge, Mass.-based Bind specializes in nanomedicine. Its Manocept platform was previously used to design the FDA-approved Lymphoseek sentinel lymph node detection agent.

Navidea Biopharmaceuticals subsidiary Macrophage developed the Manocept platform to engineer over-active macrophage treatments involved in cancer, cardiovascular, central nervous system, autoimmune, antiviral and skin diseases. It is based in Dublin, Ohio. — Jason Scott